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ABSTRACT
Objectives: This study aims to assess whether
digoxin has a different effect on mortality risk for
women than it does for men in patients with heart
failure (HF).
Design: This study uses the UK-based The Health
Information Network population database in a cohort
study of the impact of digoxin exposure on mortality
for men and women who carry the diagnosis of HF.
Digoxin exposure was assessed based on prescribing
data. Multivariable Cox proportional hazards models
were used to assess whether there was an interaction
between sex and digoxin affecting mortality hazard.
Setting: The setting was primary care outpatient
practices.
Participants: The study cohort consisted of 17707
men and 19227 women with the diagnosis of HF who
contributed only time without digoxin exposure and
9487 men and 10808 women with the diagnosis of HF
who contributed time with digoxin exposure.
Main outcome measures: The main outcome
measure was all-cause mortality.
Results: The primary outcome of this study was the
absence of a large interaction between digoxin use and
sex affecting mortality. For men, digoxin use was
associated with a HR for mortality of 1.00, while for
women, the HR was also 1.00 (p value for interaction
0.65). The results of sensitivity analyses were
consistent with those of the primary analysis.
Conclusion: Observational data do not support the
concern that there is a substantial increased risk of
mortality due to the use of digoxin in women. This
ﬁnding is consistent with previous observational
studies but discordant with results from a post hoc
analysis of a randomised controlled trial of digoxin
versus placebo.
INTRODUCTION
It has been hypothesised that digoxin, when
used in the treatment of heart failure (HF),
may increase mortality by approximately 20%
in women but not in men. This hypothesis is
based on a post hoc analysis in 6800 patients
by Rathore and colleagues of the Digitalis
Investigation Group trial, a placebo-
controlled randomised trial that showed
digoxin did not affect overall mortality but
did reduce hospitalisations in patients with
HF.
1 The post hoc analysis examined
mortality effects by sex and found that
compared with placebo digoxin conferred
reduced mortality in men (absolute differ-
ence  1.6%, 95% CI  4.2% to 1.0%) and
increased mortality in women (absolute
difference 4.2%, 95% CI  0.5% to 8.8%),
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ARTICLE SUMMARY
Article focus
- Digoxin is used in patients with HF and has been
shown in one major randomised control trial, the
Digitalis Investigation Group study, to reduce the
rate of hospitalisations in that population.
- Post hoc analysis of Digitalis Investigation Group
indicated that digoxin, when used in the
treatment of HF, may increase mortality by
approximately 20% in women but not in men.
Further randomised trials evaluating the interac-
tion between digoxin and sex have not emerged.
Key messages
- For men, digoxin use was associated with a HR
for mortality of 1.00, while for women, the HR
was also 1.00 (p value for interaction 0.65).
There was no evidence of a different association
between digoxin use and mortality in women
compared with men. Sensitivity analyses did not
affect this estimate materially.
- An interesting incidental ﬁnding of this study is
that interventions known to reduce mortality in
HF are used less in women than in men who have
been diagnosed with HF.
Strengths and limitations of this study
- The major strength of this study was its large
sample size, which allowed adjustment for many
covariates and numerous sensitivity analyses,
none of which affected the conclusions.
- The major limitation of this study is that it is non-
randomised. Although there is no evidence of
substantial confounding of the main study result,
confounding could still bias these results.
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Open Access Researchwith a statistically signiﬁcant interaction (p value
¼0.034).
2 One proposed mechanism is that women may
have higher mean serum digoxin levels than men. There
is evidence that even within the therapeutic range,
higher serum digoxin levels are associated with
increased mortality, and experts have argued that
maintenance of serum digoxin levels at the low end of
the therapeutic range may be the key to safe, effective
use of the drug in either sex.
3 7
Because the sexedigoxin interaction was based on
post hoc analyses, it needs cautious interpretation. Yet, if
true, the ﬁnding is clinically important because digoxin
continues to be widely used by both women and men.
8 It
remains unclear whether digoxin should be used
differently in the different sexes, and concerns about its
use in women continue to appear in the literature.
91 0
Unwarranted recommendations against use of digoxin
in women would deprive a large population of a
medicine with demonstrated ability to prevent
hospitalisations.
Further randomised trials evaluating the interaction
between digoxin and sex have not emerged. One
observational study based on the Studies of Left
Ventricular Dysfunction cohort found no difference in
digoxin’s effect on mortality between sexes but
concluded that additional research in other populations
is still needed.
10 Limitations of that study included
restriction to a population with severely reduced ejection
fraction (<35%) and relatively small sample size
(n¼6797). Another observational study performed on
2841 propensity score-matched patients with HF also did
not report any difference in digoxin’s effect on mortality
between the sexes; this study was primarily limited by
a relatively small size and restriction to a single clinical
center.
11 We sought to conduct a much larger study in
a broader population that could help assess whether
digoxin increases mortality in women compared with
men.
METHODS
Study design
We conducted a retrospective cohort study to test the
primary null hypothesis that sex was not an effect
modiﬁer for the association of digoxin use with
mortality. We also conducted planned secondary anal-
yses of whether effect modiﬁcation was mediated by
digoxin dose or by serum digoxin concentration. This
study was approved by the Institutional Review Board of
the University of Pennsylvania. Analyses were conducted
using SAS V.9.1.
Study population
The study used the Health Improvement Network
(THIN) Database, a primary care electronic medical
record database in the UK. This database contains over 5
million individuals who have contributed person-time
from over 300 different general practices from 1986 to
2008. THIN includes demographic information on
patients, as well as records of prescribed drugs, medical
diagnoses (coded as READ codes), as well as vital signs
and laboratory values on a subset of patients. It is
a representative subset of the UK’s general population.
12
Cohort deﬁnition
The analysis was restricted to individuals with a diag-
nostic code for HF. Once that condition was met,
patients could contribute follow-up time as long as they
were being given regular prescriptions of at least one
drug consistent with the treatment for HF (as described
below). Information was only used if it was collected
during times when the adjusted mortality ratio, a quality
control measure used in THIN to identify practices
which are recording deaths accurately, was within
acceptable standards for a given practice.
13 It was
possible for one individual to contribute both exposed
and unexposed time. The result was four cohorts with
some within-sex cross-over: men on digoxin, men not on
digoxin, women on digoxin and women not on digoxin.
Exposed group
Exposed subjects were deﬁned as individuals who carried
the diagnosis of HF and were receiving two or more
consecutive prescriptions for digoxin. Individuals were
assumed to be on digoxin from the date of receipt of
a prescription until 30 days after their prescription ran
out (the intended duration of a prescription was either
computed from information on daily dose and number
of tablets or imputed as 30 days if that information was
not available).
Unexposed group
Unexposed subjects were deﬁned as individuals who
carried a diagnosis of HF and were receiving two or more
consecutive prescriptions for a loop diuretic, b blocker,
ACE inhibitor or angiotensin receptor blocker. They
only contributed person-time to the cohort while
receiving these drugs; they were assumed to be on a drug
from the date of receipt of a prescription until 30 days
after their prescription ran out, which was deﬁned with
the same criteria used for digoxin exposure. These are
drugs that, while not speciﬁc for HF, are commonly used
for that condition.
Deﬁnition of outcome
The outcome for this study was all-cause mortality, as
documented by a date of death in the THIN demo-
graphics ﬁle.
Deﬁnition of covariates
Baseline covariates consisted of diagnostic codes for
common comorbidities of HF, including hypertension,
stroke, myocardial infarction, chronic obstructive
pulmonary disease, diabetes and atrial ﬁbrillation. We
also assessed age, sex and baseline use of drugs
commonly used in HF, notably aspirin, statins, oral
anticoagulants, potassium-sparing diuretics and the HF-
associated drugs listed above. To be included as
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Cohort study of the safety of digoxin in women with heart failurea baseline variable, drug use had to be in the year prior
to HF diagnosis; medical history such as a history of
hypertension could be coded at any time prior to HF
diagnosis. Blood pressure, body mass index (BMI) and
a variety of laboratory values including serum creatinine
were available on a minority of participants and were
used as baseline variables in sensitivity analysis. Once
a patient began to contribute exposure time, baseline
variables were no longer updated.
Statistical analysis
Because of the large sample size, we anticipated that
even clinically insigniﬁcant differences between baseline
variables could be statistically signiﬁcant and therefore
described baseline variables using standardised differ-
ences.
14 Standardised differences are a balance diag-
nostic used to assess how similar groups are at
baselinedconceptually, they are equal to the difference
of a variable’s mean between two groups divided by the
SD for that variable. A standardised difference of <0.1,
by convention, is considered to indicate good balance of
groups on that variable.
14 For categorical variables,
a standardised difference between men and women was
calculated as
pwomen   pmen ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
pwomenð1   pwomenÞþpmenð1   pmenÞ
2
r ,
where p ¼ proportion of the population falling into
a category. In addition, because the most relevant ques-
tion was whether these between-sex differences were
consistent in both digoxin-exposed and digoxin-
unexposed groups, this equation was extended to treat
the inter-sex differences for the exposed and unexposed
groups as variables which in turn had their own
standardised differences:
Total follow-up time for all individuals was assessed,
with digoxin use, digoxin dose and serum digoxin
concentrations as time-varying covariates in secondary
analysis. In the primary analysis, digoxin dose and serum
concentration were ignored. A Cox proportional hazards
model was used to calculate HRs for sex, digoxin use and
the interaction of sex and digoxin use, controlling for
the covariates speciﬁed above.
15
The primary parameter of interest was the adjusted
HR for the interaction of sex and digoxin use, where
a signiﬁcant deviation from the null would indicate that
digoxin use was associated with mortality differently for
men than for women. Speciﬁcally, a HR for interaction
signiﬁcantly greater than one would indicate that
digoxin was associated with greater mortality in women
than in men. This analysis was then repeated with
inclusion of digoxin dose and then serum digoxin level
in the model to assess for any evidence that these vari-
ables mediated any interaction. Finally, sensitivity anal-
yses were conducted in which baseline blood pressure,
BMI and serum creatinine were included in the analysis,
in which the cohort was restricted to participants using
concomitant loop diuretics, in which comorbid condi-
tions were deﬁned based only on data from the 1 year
preceding cohort entry, in which patients with a diag-
nosis of atrial ﬁbrillation were excluded, in which data
were included even if the adjusted mortality ratio at the
time of collection was not acceptable and in which
subjects were excluded as soon as they crossed over from
one exposure group into another.
RESULTS
Characteristics of the study population
The study cohort consisted of 17707 men and 19227
women who contributed time only without digoxin
exposure and 9487 men and 10808 women who
contributed time with digoxin exposure. Table 1 pres-
ents differences in baseline variables between these
groups. In general, many variables were differently
distributed between sexes, as reﬂected by high stand-
ardised differences. However, sex differences were
consistent between digoxin-exposed and unexposed
groups, as reﬂected by low standardised differences of
differences (<0.1 for all variables).
Baseline drug utilisation data were notable for high
rates of loop diuretic use (table 1). Oral anticoagulant
use was much more common among digoxin users even
after controlling for baseline diagnosis of atrial ﬁbrilla-
tion. Examination of trends in drug use during the year
after the diagnosis of HF was documented (ﬁgure 1)
shows rapid increases in the use of ACE inhibitors,
b blockers and spironolactone, with higher rates of
use of all these agents in men compared with women
(ﬁgure 1A,B).
Blood pressure was recorded for the majority of
subjects, while other quantitative covariates such as BMI
and serum creatinine were recorded on a minority of
subjects. In general, rates of missing data were higher for
women than for men. Baseline systolic BP mean >140
was considerably more common in women, while
a serum creatinine greater than 150 mg/dl was consid-
erably more common in men.
Digoxin prescribing patterns over time
We found that digoxin use among subjects in this study
remained prevalent at about 25% throughout the time
period covered by the database (ﬁgure 1A,B).
h 
pwomen; exposed  pmen; exposed
 
 
 
pwomen; unexposed  pmen; unexposed
 i
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ h 
pwomen; exposed
 
1 pwomen; exposed
 
þ pmen; exposed
 
1 pmen; exposed
 
þ pwomen; unexposed
 
1 pwomen; unexposed
 
þ pmen; unexposed
 
1 pmen; unexposed
  i
4
s :
Flory JH, Ky B, Haynes K, et al. BMJ Open 2012;2:e000888. doi:10.1136/bmjopen-2012-000888 3
Cohort study of the safety of digoxin in women with heart failureDigoxin dose was consistently lower in women than
in men (mean daily dose 136 mg in women and 159 mg
in men, p<0.001), and the average dose in both groups
declined over time by 1.6 mg/year in men and 1.3 mg/
year in women (p<0.001 for both trends but no signiﬁ-
cant difference in the rate of decline for men vs women).
Serum digoxin levels were available for 8563 separate
measurements covering 4063 individuals. The mean
serum level for men was 1.2 ng/dl, while for women, it
was 1.3 ng/dl (p<0.0001 for difference). Linear regres-
sion of digoxin level against date yielded an annual
decline in mean digoxin level of 0.02 ng/dl/year in men
and 0.01 ng/dl/year in women (p<0.0001 for men and
p¼0.01 for women, non-signiﬁcant difference in rate
between men and women).
Outcomes
Death rates after HF diagnosis without adjustment
showed similar rates of mortality in all four cohorts
deﬁned by sex and digoxin use (table 2).
Table 1 Demographic and clinical features of cohort
Digoxin
non-use Standardised
difference
Digoxin use Standardised
difference
Standardised
difference
of differences Male Female Male Female
Total (N) 17707 19227 9487 10808
Baseline demographics
Age <50 3% 2% 0.08 2% 1% 0.11 0.01
Age 50e64 16% 8% 0.25 15% 5% 0.31 0.02
Age 65e74 28% 22% 0.15 30% 19% 0.25 0.07
Age >74 52% 68% 0.33 54% 75% 0.45 0.08
Baseline medical history
History of MI 28% 15% 0.33 22% 12% 0.28 0.05
History of stroke 14% 13% 0.04 14% 14% 0.00 0.03
History of diabetes 20% 15% 0.12 16% 13% 0.10 0.02
History of hypertension 44% 49% 0.10 41% 45% 0.09 0.01
History of COPD 14% 11% 0.11 13% 8% 0.16 0.02
History of fracture 7% 12% 0.19 6% 11% 0.18 0.01
History of pneumonia 4% 3% 0.02 4% 3% 0.05 0.02
History of atrial
ﬁbrillation
10% 8% 0.09 41% 41% 0.00 0.05
Baseline drug use
Statin user 25% 16% 0.23 15% 10% 0.18 0.06
Loop diuretic user 53% 56% 0.06 59% 58% 0.01 0.05
Aspirin user 42% 32% 0.21 35% 30% 0.11 0.08
Oral anticoagulant user 9% 5% 0.15 24% 18% 0.13 0.03
Nitrate user 31% 24% 0.15 26% 20% 0.13 0.02
K-Sparing diuretic user 20% 25% 0.13 24% 29% 0.09 0.02
Spironolactone user 5% 4% 0.04 6% 5% 0.04 0.00
b Blocker user 26% 22% 0.10 19% 18% 0.03 0.05
ACE user 36% 28% 0.18 35% 27% 0.18 0.00
ARB user 6% 6% 0.02 5% 5% 0.01 0.02
Thiazide user 16% 23% 0.18 16% 22% 0.16 0.02
CCB user 27% 24% 0.08 23% 21% 0.04 0.03
Laboratory data and vital signs
BMI
% with data 36% 27% 0.20 32% 24% 0.19 0.01
BMI <18 1% 3% 0.16 1% 4% 0.21 0.05
BMI 18e25 27% 30% 0.07 31% 37% 0.13 0.05
BMI 25e30 41% 31% 0.22 41% 31% 0.21 0.00
BMI 30e35 22% 20% 0.03 19% 16% 0.06 0.02
BMI >35 10% 16% 0.18 9% 12% 0.09 0.07
Creatinine
% with data 40% 33% 0.14 33% 29% 0.09 0.04
Cr >150 16% 8% 0.23 14% 7% 0.23 0.01
Blood pressure
% with data 71% 65% 0.12 66% 61% 0.10 0.02
SBP >140 50% 60% 0.21 47% 58% 0.22 0.01
ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease;
Cr, creatinine; MI, myocardial infarction; SBP, systolic blood pressure.
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Cohort study of the safety of digoxin in women with heart failureMultivariable modelling was pursued in stages (table
3). Brieﬂy, we found that when universally available
variables were adjusted for as covariates, there was no
evidence of interaction between sex and digoxin use.
The adjusted HR for digoxin exposure in a cohort
restricted to women was 1.00 (95% CI 0.96 to 1.06)
and for a cohort restricted to men it was identical: 1.00
(95% CI 0.95 to 1.06). A fully adjusted Cox proportional
hazards model with a term for the interaction between
digoxin use and sex yielded an interaction HR of 1.02
Figure 1 Trends in drug use
among (A) men and (B) women.
Table 2 Event rates
N Total person-years Deaths
Deaths per
person-year
Male digoxin non-user 17707 53244 4616 0.09
Male digoxin user 19227 60648 5076 0.08
Female digoxin non-user 9487 24804 2324 0.09
Female digoxin user 10808 30056 2782 0.09
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Cohort study of the safety of digoxin in women with heart failure(95% CI 0.95 to 1.09), where a HR signiﬁcantly >1
would have indicated that digoxin use in women
conferred a greater hazard of death than in men.
We examined whether the dose of digoxin mediated
any interaction between sex and exposure by including
digoxin dose in the model both as an independent vari-
able and as an interaction term with sex, both as a cate-
gorical and a continuous variable. The same was done
with serum digoxin levels. None of these analyses yielded
any signiﬁcant interaction terms. Low levels of digoxin in
the serum (<0.9 ng/dl) were associated with lower
mortality than higher levels (HR 0.71, 95% CI 0.67 to
0.76, p¼0.007), and this association did not differ by sex.
Sensitivity analyses including restriction of the cohort
to persons actively taking loop diuretics, permitting use
of data without the adjusted mortality ratio being up to
standard, analysing the subset of the population with
blood pressure, BMI and serum creatinine available,
deﬁning comorbid conditions based only on data from
the 1 year preceding cohort entry, excluding patients
with a diagnosis of atrial ﬁbrillation and excluding
persons at the time of cross-over to a different exposure
category, all conﬁrmed the results of the primary anal-
ysis, never showing a substantial or statistically signiﬁcant
interaction between sex and digoxin and mortality.
DISCUSSION
The primary ﬁnding from this study was the absence of
a large interaction between digoxin use and sex
affecting mortality, with a 95% CI excluding a HR >1.09
for the interaction. This suggests that the association
between digoxin and mortality is similar in women and
men. Sensitivity analyses did not affect this estimate
materially.
The other prespeciﬁed aims of the study were to assess
whether any interaction might be mediated by digoxin
dose or by higher serum digoxin levels, both of which are
thought to potentially affect mortality rates.
3e7 Analyses
incorporating digoxin dose and serum digoxin levels
showed no evidence of such mediation. We did note an
association between lower serum digoxin levels and lower
mortality, but since such an association could easily be
strongly confounded (eg, if more symptomatic patients
were pushed to higher serum digoxin levels), this paper
does not directly support or refute the claim that lower
serum levels of digoxin lead to lower mortality risk.
An interesting incidental ﬁnding was rapid increases in
the rates of b blocker, ACE and spironolactone use
beginning at the same time that major studies were pub-
lished establishing that these drugs prevented mortality in
HF.
16 18 Comparison by sex shows that while overall
trends are similar, women consistently have lower levels of
use of these life-saving agents compared with men.
A major strength of this study is its large sample size,
permitting precise point estimates of associations. The
size of the database also permitted numerous sensitivity
analyses on subpopulations. The lack of interaction
between sex and digoxin use was robust to adjustment
for numerous potential confounders and to all sensitivity
analyses. The major limitation of this study is that it is
non-randomised. Although there is no evidence of
substantial confounding of the main study result,
confounding could still bias these results. Access to
additional information that was not recorded in THIN,
Table 3 Model with all universally available baseline variables
HR Lower CI Upper CI p Value
Sex 3 digoxin interaction 1.02 0.95 1.09 0.65
Digoxin use 1.00 0.95 1.05 0.89
Female sex 0.86 0.83 0.90 <0.0001
Year of CHF diagnosis 0.99 0.98 0.99 <0.0001
Age 50e64 years 0.42 0.40 0.44 <0.0001
Age 65e74 years 0.58 0.56 0.60 <0.0001
Hypertension 0.91 0.88 0.94 <0.0001
Stroke 1.34 1.29 1.40 <0.0001
MI 1.15 1.11 1.20 <0.0001
COPD 1.36 1.30 1.43 <0.0001
Fracture 1.08 1.03 1.14 0.001
Diabetes 1.34 1.28 1.40 <0.0001
Atrial ﬁbrillation 0.93 0.89 0.97 0.001
Loop diuretic use 1.27 1.23 1.32 <0.0001
Potassium-sparing diuretic
use
1.07 1.03 1.11 0.00
Thiazide diuretic 1.03 0.99 1.07 0.16
Oral anticoagulant use 0.92 0.87 0.98 0.001
b Blocker use 0.83 0.79 0.86 <0.0001
ACE use 0.97 0.93 1.00 0.07
ARB use 0.90 0.82 0.98 0.01
CCB use 0.93 0.90 0.97 0.001
ARB, angiotensin receptor blocker; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; MI, myocardial infarction.
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Cohort study of the safety of digoxin in women with heart failureparticularly the type (systolic vs diastolic) and severity of
HF, would have been helpful but only a randomised trial
(ideally a series of such trials in various populations and
dosing regimens) could deﬁnitively avoid concerns
about confounding.
The outcome of this study is discordant with the post
hoc analysis of the DIG trial
2 but consistent with two
prior observational studies that did not observe any
digoxinesex interaction.
10 11 It complements those prior
studies by having over eight times their sample sizes and
a more diverse cohort. Because the ﬁnding of an inter-
action from the DIG trial was the result of post hoc
analysis, it is conceivable that the ﬁnding was a type 1
error (false positive), but it is also possible that the DIG
trial results were correct, and the observational results
are biased by unmeasured confounders that affected the
interaction analysis. An interesting incidental ﬁnding of
this study is that interventions known to reduce mortality
in HF are used less in women than in men who carry that
diagnosis (ﬁgure 1A,B).
16e18 It would be premature to
conclude that these differences necessarily imply worse
care since there are important differences between the
male and female populations with HF that might legiti-
mately affect prescribing practices. However, the
systematic differences in drug usage between the sexes
deserve further investigation.
In conclusion, this study did not identify a difference
between the sexes in the hazard of death associated with
the use of digoxin. These results are of use in the context
of a clinical questiondwhether digoxin can be used as
safely in women as it can in mendfor which there are
few randomised data. These results suggest that this
drug, with its proven ability to reduce the need for
hospitalisation, is still a viable therapeutic option in
women with HF.
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